The role of the androgen receptor in prostate cancer

Critical Reviews in Eukaryotic Gene Expression

Volumn 12, Issue 3, 2002, Pages 193-207

  Huang, Haojie ^a   Tindall, Donald J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Androgen receptor; Androgen regulated genes; Androgens; Prostate cancer

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANDROGEN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; EPIGALLOCATECHIN GALLATE; ESTROGEN; GROWTH FACTOR; POLYPHENOL DERIVATIVE; PROGESTERONE; UO 126;

CANCER CELL; CELL SURVIVAL; DISEASE ACTIVITY; DISEASE COURSE; GENE CONTROL; HUMAN; LIPOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; CELL CYCLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC;

EID: 0038112654     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukaryotGeneExpr.v12.i3.30     Document Type: Review

References (151)

1. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, Milbrandt J (2002): Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 22:1495-1503.
2. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI (1999): Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91:1869-1876.
3. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-Shen C, Shen MM (1999): Roles for Nkx3.1 in prostate development and cancer. Genes Dev 13:966-977.
4. Blok LJ, Grossmann ME, Perry JE, Tindall DJ (1995): Characterization of an early growth response gene, which encodes a zinc finger transcription factor, potentially involved in cell cycle regulation. Mol Endocrinol 9:1610-1620.
5. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP, Gelmann EP (2000): Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 60:6111-6115.
6. Brawer MK (1995): Prostate cancer. J Urol 153:115-116.
7. Brinkmann AO, Trapman J (2000): Prostate cancer schemes for androgen escape. Nat Med 6:628-629.
8. Carbini LA, Scicli AG, Carretero OA (1993): The molecular biology of the kallikrein-kinin system: III. The human kallikrein gene family and kallikrein substrate. J Hypertens 11:893-898.
9. Chamberlain NL, Driver ED, Miesfeld RL (1994): The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22:3181-3186.
10. Chen T, Wang LH, Farrar WL (2000): Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60:2132-2135.
11. Choong CS, Wilson EM (1998): Trinucleotide repeats in the human androgen receptor: a molecular basis for disease. J Mol Endocrinol 21:235-257.
12. Chung BH, Mitchell SH, Zhang JS, Young CY (2001): Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis 22:1201-1206.
13. Craft N, Sawyers CL (1998-1999): Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev 17:421-427.
14. Craft N, Shostak Y, Carey M, Sawyers CL (1999): A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285.
15. Cronauer MV, Nessler-Menardi C, Klocker H, Maly K, Hobisch A, Bartsch G, Culig Z (2000): Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells. Br J Cancer 82:39-45.
16. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H (1993): Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541-1550.
17. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H (1994): Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478.
18. Culig Z, Hobisch A, Herold M, Hittmair A, Thurnher M, Eder IE, Cronauer MV, Rieser C, Ramoner R, Bartsch G, Klocker H, Konwalinka G (1998a): Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells. Br J Cancer 78:1004-1011.
19. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato AC, Bartsch G, Klocker H (1998b): Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35:63-70.
20. Datta SR, Brunet A, Greenberg ME (1999): Cellular survival: a play in three Akts. Genes Dev 13:2905-2927.
21. Ding VD, Moller DE, Feeney WP, Didolkar V, Nakhla AM, Rhodes L, Rosner W, Smith RG (1998): Sex hormone-binding globulin mediates prostate androgen receptor action via a novel signaling pathway. Endocrinology 139:213-218.
22. Dorgan JF, Judd JT, Longcope C, Brown C, Schatzkin A, Clevidence BA, Campbell WS, Nair PP, Franz C, Kahle L, Taylor PR (1996): Effects of dietary fat and fiber on plasma and urine androgens and estrogens in men: a controlled feeding study. Am J Clin Nutr 64:850-855.
23. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Lukkarinen O, Vihko P (1995): Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 80:3494-3500.
24. Fasciana C, van der Made AC, Faber PW, Trapman J (1996): Androgen regulation of the rat keratinocyte growth factor (KGF/FGF7) promoter. Biochem Biophys Res Commun 220:858-863.
25. Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A (1998): Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 139:451-456.
26. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML, Pestell RG (2000): p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275:20853-20860.
27. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C (1999): Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 274:8316-8321.
28. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996). Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88: 1118-1126.
29. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994): Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54:2861-2864.
30. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW (1997): The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94:3320-3323.
31. Gong Y, Blok LJ, Perry JE, Lindzey JK, Tindall DJ (1995): Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology 136:2172-2178.
32. Gottlieb B, Beitel LK, Lumbroso R, Pinsky L, Trifiro M (1999): Update of the androgen receptor gene mutations database. Hum Mutat 14:103-114.
33. Graff JP, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL (2000): Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275: 24500-24505.
34. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS (1998): Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58:5718-5724.
35. Gregory CW, Kim D, Ye P, D'Ercole AJ, Pretlow TG, Mohler JL, French FS (1999): Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology 140:2372-2381.
36. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM (2001): Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898.
37. Grigoryev DN, Long BJ, Njar VC, Brodie AH (2000): Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J Steroid Biochem Mol Biol 75:1-10.
38. Grossmann ME, Huang H, Tindall DJ (2001): Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697.
39. Hamalainen E, Adlercreutz H, Puska P, Pietinen P (1984): Diet and serum sex hormones in healthy men. J Steroid Biochem 20:459-464.
40. Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, Nanus DM, Catterall JF (1996): Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 81:4400-4405.
41. Hayes SA, Zarnegar M, Sharma M, Yang F, Peehl DM, ten Dijke P, Sun (2001): SMAD3 represses androgen receptor-mediated transcription. Cancer Res 61: 2112-2118.
42. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, Curtis RT, Shell BK, Bostwick DG, Tindall DJ, Gelmann EP, Abate-Shen C, Carter KC (1997): A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43:69-77.
43. Heemers H, Maes B, Foufelle F, Heyns W, Verhoeven G, Swinnen JV (2001): Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 15:1817-1828.
44. Henttu P, Vihko P (1993): Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. Cancer Res 53:1051-1058.
45. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A (1995): Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55:3068-3072.
46. Hobisch A, Eder IE, Putz T, Hominger W, Bartsch G, Klocker H, Culig Z (1998): Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58:4640-4645.
47. Hofman K, Swinnen JV, Verhoeven G, Heyns W (2001): E2F activity is biphasically regulated by androgens in LNCaP cells. Biochem Biophys Res Commun 283:97-101.
48. Hsieh TY, Ng CY, Mallouh C, Tazaki H, Wu JM (1996): Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun. 223:141-146.
49. Huang H, Reed CP, Zhang JS, Shridhar V, Wang L, Smith DI (1999): Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Res 59:2981-2988.
50. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ (2001): PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bd-2 expression. J Biol Chem 276:38830-38836.
51. Huggins C, Hodges CV (1941): Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297.
52. Ikonen T, Palvimo JJ, Kallio PJ, Reinikainen P, Janne OA (1994): Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology 135:1359-1366.
53. Irvine RA, Yu MC, Ross RK, Coetzee GA (1995): The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55:1937-1940.
54. Jenster G, de Ruiter PE, van der Korput HA, Kuiper GG, Trapman J, Brinkmann AO (1994): Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. Biochemistry 33:14064-14072.
55. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT (1997): Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 3:2507-2511.
56. Kang HY, Yeh S, Fujimoto N, Chang C (1999): Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 274:8570-8576.
57. Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang CY (2001): From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA 8:3018-3023.
58. Kantoff P, Giovannucci E, Brown M (1998): The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Biochim Biophys Acta 1378:C1-C5.
59. Kazemi-Esfarjani P, Trifiro MA, Pinsky L (1995): Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet 4:523-527.
60. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, Abate-Shen C (2002): Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 99:2884-2889.
61. Knudsen KE, Arden KC, Cavenee WK (1998): Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 273:20213-20222.
62. Knudsen KE, Cavenee WK, Arden KC (1999): D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 59:2297-2301.
63. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP (1997): Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314-319.
64. Koivisto PA, Schleutker J, Helin H, Ehren-van Eekelen C, Kallioniemi OP, Trapman J (1999): Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clin Cancer Res 5:3578-3582.
65. Kokontis J, Takakura K, Hay N, Liao S (1994): Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 54:1566-1573.
66. Kokontis JM, Hay N, Liao S (1998): Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12:941-953.
67. Korsmeyer SJ (1999): BCL-2 gene family and the regulation of programmed cell death. Cancer Res 59:1693s-1700s.
68. Krongrad A, Wilson CM, Wilson JD, Allman DR, McPhaul MJ (1991): Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol 76:79-88.
69. Kumar MV, Jones EA, Felts SJ, Blexrud MD, Grossmann ME, Blok LJ, Schmidt LJ, Tindall DJ (1998): Characterization of a TPA-response element in the 5′-flanking region of the androgen receptor gene. J Androl 19:595-602.
70. Kyprianou N, English HF, Isaacs JT (1990): Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748-3753.
71. Lapointe J, Fournier A, Richard V, Labrie C (1999): Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology 140:416-421.
72. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM (1995): Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136:796-803.
73. Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Holland JF, Kirschenbaum A (1998): Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139:4672-4678.
74. Li P, Nicosia SV, Bai W (2001): Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem 276:20444-20450.
75. Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA (1995): Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 96:239-243.
76. Lin HK, Yeh S, Kang HY, Chang C (2001): Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 98:7200-7205.
77. Lindzey J, Grossmann M, Kumar MV, Tindall DJ (1993): Regulation of the 5′-flanking region of the mouse androgen receptor gene by cAMP and androgen. Mol Endocrinol 7:1530-1540.
78. Lu S, Tsai SY, Tsai MJ (1997): Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 57:4511-4516.
79. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ (1999): Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13:376-384.
80. Lu S, Jenster G, Epner DE (2000): Androgen induction of cydin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol 14:753-760.
81. Ma H, Hong H, Huang SM, Irvine RA, Webb P, Kushner PJ, Coetzee GA, Stallcup MR (1999): Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol 19:6164-6173.
82. Maehama T, Dixon JE (1998): The tumor suppressor, PTEN/MMAC1, dephosphorylates the: lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375-13378.
83. Mahendroo MS, Russell DW (1999): Male and female isoenzymes of steroid 5alpha-reductase. Rev Reprod 4: 179-183.
84. Marti A, Wirbelauer C, Scheffner M, Krek W (1999): Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1:14-19.
85. McDonald S, Brive L, Agus DB, Scher HI, Ely KR (2000): Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res 60:2317-2322.
86. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML (1992): Expression of the protooncogene bd-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944.
87. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR (1999): Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59:4291-4296.
88. Mitchell SH, Zhu W, Young CY (1999): Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59:5892-5895.
89. Mitchell SH, Murtha PE, Zhang S, Zhu W, Young CY (2000): An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene. Mol Cell Endocrinol 168:89-99.
90. Miyamoto H, Yeh S, Wilding G, Chang C (1998): Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 95:7379-7384.
91. Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, Chang HC, Nishimura K, Fujimoto N, Chang C (2002): A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem 277:4609-4617.
92. Mizokami A, Yeh SY, Chang C (1994): Identification of 3′,5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol Endocrinol 8:77-88.
93. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ (2001): Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142:4795-4805.
94. Nazareth LV, Weigel NL (1996): Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 271:19900-19907.
95. Nickerson T, Miyake H, Gleave ME, Pollak M (1999): Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res 59:3392-3395.
96. Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T (1997): Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 31:216-219.
97. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM (1998): Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4:50-57.
98. Perry JE, Tindall DJ (1996): Androgens regulate the expression of proliferating cell nuclear antigen post-transcriptionally in the human prostate cancer cell line, LNCaP. Cancer Res 56:1539-1544.
99. Petre CE, Wetherill YB, Danielsen M, Knudsen KE (2002): Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem 277:2207-2215.
100. Pienta KJ, Esper PS (1993): Risk factors for prostate cancer. Ann Intern Med 118:793-803.
101. Prescott JL, Blok L, Tindall DJ (1998): Isolation and androgen regulation of the human homeobox cDNA, NKX3.1. Prostate 35:71-80.
102. Prescott JL, Tindall DJ (1998): Clathrin gene expression is androgen regulated in the prostate. Endocrinology 139:2111-2119.
103. Quarmby VE, Yarbrough WG, Lubahn DB, French FS, Wilson EM (1990): Autologous down-regulation of androgen receptor messenger ribonudeic acid. Mol Endocrinol. 4:22-28.
104. Ren F, Zhang S, Mitchell SH, Butler R, Young CY (2000): Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 19:1924-1932.
105. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ, Pestell RG (2001): Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 15:797-811.
106. Sadar MD (1999): Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 274:7777-7783.
107. Sadar MD, Gleave ME (2000): Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res 60:5825-5831.
108. Sadi MV, Walsh PC, Barrack ER (1991): Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67:3057-3064.
109. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P, Korsmeyer SJ (1988): Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 7:123-131.
110. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR (1996): Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271:7043-7051.
111. Schuurmans AL, Bolt J, Veldscholte J, Mulder E (1990): Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Mol Biol 37:849-853.
112. Sheflin L, Keegan B, Zhang W, Spaulding SW (2000): Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem Biophys Res Commun 276:144-150.
113. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, Ostrander EA (1997): Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57:1194-1198.
114. Sumitomo M, Milowsky MI, Shen R, Navarro D, Dai J, Asano T, Hayakawa M, Nanus DM (2001): Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 61:3294-3298.
115. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J (1993): Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759-765.
116. Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W, Verhoeven G (1996): Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 137:4468-4474.
117. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven (1997): Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 57:1086-1090.
118. Swinnen JV, Ulrix W, Heyns W, Verhoeven G (1997): Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc Natl Acad Sci USA 94:12975-12980.
119. Swinnen JV (2001): Increased lipogenesis in steroid-responsive cancer cells: mechanisms of regulation, role in cancer cell biology and perspectives on clinical applications. Verh K Acad Geneeskd Belg 63:321-333.
120. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W, Verhoeven G (2002): Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98:19-22.
121. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS (1997): Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11:450-459.
122. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995): Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398.
123. Truica CI, Byers S, Gelmann EP (2000): Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60:4709-4713.
124. Tsai MJ, O'Malley BW (1994): Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486.
125. Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J (2000): Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 19:670-679.
126. Ueda T, Bruchovsky N, Sadar MD (2002): Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277:7076-7085.
127. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV (2002): Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 62:642-646.
128. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, Trapman J (1991): Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189-193.
129. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E (1990): A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540.
130. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995): In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406.
131. Voeller HJ, Augustus M, Madike V, Bova GS, Carter KC, Gelmann EP (1997): Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res 57:4455-4459.
132. Voeller HJ, Truica CI, Gelmann EP (1998): Beta-catenin mutations in human prostate cancer. Cancer Res 58:2520-2523.
133. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M (2001): Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 15:765-782.
134. Wang X, Yeh S, Wu G, Hsu CL, Wang L, Chiang T, Yang Y, Guo Y, Chang C (2001): Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells. J Biol Chem 276:40417-40423.
135. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC (2000): HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841-6845.
136. Wilson JD (1996): Role of dihydrotestosterone in androgen action. Prostate suppl 6:88-92.
137. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL (1998): The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95:15587-15591.
138. Xing N, Chen Y, Mitchell SH, Young CY 2001): Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22:409-414.
139. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z (2002): Linking beta-catenin to androgen-signaling pathway. J Biol Chem 277:11336-11344.
140. Yamamoto A, Hashimoto Y, Kohri K, Ogata E, Kato S, Ikeda K, Nakanishi M (2000): Cyclin E as a coactivator of the androgen receptor. J Cell Biol 150:873-880.
141. Ye D, Mendelsohn J, Fan Z (1999). Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res 5:2171-2177.
142. Yeh S, Chang C (1996): Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93:5517-5521.
143. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C (1999): From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96:5458-5463.
144. Yeap BB, Krueger RG, Leedman PJ (1999): Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 140:3282-3291.
145. Young CY, Andrews PE, Tindall DJ (1995): Expression and androgenic regulation of human prostate-specific kallikreins. J Androl 6:97-99.
146. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ (2002): Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013.
147. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D (1999): Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 162:2192-2199.
148. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D (2000): Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6:703-706.
149. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC (2000): HER-2/ neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275:8027-8031.
150. Zhu W, Smith A, Young CY (1999): A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology 140:5451-5454.
151. Zhu W, Zhang JS, Young CY (2001): Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 22:1399-1403.